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Abstract
Vasopressin, endothelin and adrenomedullin are vasoactive peptides that regulate vascular tone and might play a role in
hypertensive diseases. Recently, laboratory assays have been developed to measure stable fragments of vasopressin,
endothelin and adrenomedullin. Little is known about their diagnostic and prognostic value in hemodialysis patients. In this
study, we measured the plasma concentration of copeptin, mid-regional-pro-adrenomedullin (MR-pro-ADM) and C-terminal
pro-endothelin 1 (CT-pro-ET1) in stable ambulatory hemodialysis patients (n = 239) and investigated their associations with
clinical factors and mortality. In all patients enrolled, the plasma concentrations of copeptin, MR-pro-ADM and CT-pro-ET1
were largely elevated with a median concentration of 132 pmol/L (interquartile range [IQR] 78–192) for copeptin, 1.26 nmol/
L (IQR 1.02–1.80) for MR-pro-ADM and 149 pmol/L (IQR 121–181) for CT-pro-ET1. The plasma concentrations of all vasoactive
peptide fragments correlated with time on dialysis and plasma b2-microglobulin concentration and were negatively
correlated to residual diuresis. The plasma concentration of MR-pro-ADM was a strong predictor of all-cause (univariate
hazard ratio for a 10-fold increase 9.94 [3.14;32], p,0.0001) and cardiovascular mortality (hazard ratio 34.87 [5.58;217],
p = 0.0001) within a 3.8-year follow-up. The associations remained stable in models adjusted for dialysis specific factors and
were attenuated in a full model adjusted for all prognostic factors. Plasma copeptin concentration was weakly associated
with cardiovascular mortality (only in univariate analysis) and CT-pro-ET1 was not associated with mortality at all. In
conclusion, vasoactive peptide fragments are elevated in hemodialysis patients because of accumulation and, most likely,
increased release. Increased concentrations of MR-pro-ADM are predictive of mortality.
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Introduction
Vasopressin, endothelin and adrenomedullin are vasoactive
peptides that regulate vascular tone and perfusion. After being
released by vascular endothelial cells (endothelin and adrenome-
dullin) or pituitary gland (vasopressin), these peptides exert their
actions in vascular smooth muscle cells after binding to specific G-
protein coupled receptors and generating second messengers.
Whereas vasopressin and endothelin lead to vasoconstriction,
adrenomedullin exhibits vasodilatory effects [1]. All three have in
common a short half-life of a few minutes and ex vivo instability
that has precluded valid measurements in humans. To overcome
this problem, laboratory assays that detect stable fragments of
vasopressin, endothelin and adrenomedullin have been developed,
thereby enabling applications in different patient cohorts and
diseases [2–4]. Copeptin, the C-terminal portion of pro-vasopres-
sin, C-terminal endothelin 1 (CT-pro-ET1) and mid-regional-pro-
adrenomedullin (MR-pro-ADM) are small peptide fragments with
39, 44 and 47 amino acids in length, respectively, that are excised
from large precursor peptides during posttranslational processing.
They share a low molecular weight (3.4 kDa for copeptin, 5.2 kDa
for CT-pro-ET1 and 5.1 kDa for MR-pro-ADM) and because
they are stoichiometrically generated they can serve as a good
estimate for the plasma concentrations of vasopressin, endothelin
and adrenomedullin.
Accurate risk prediction is an important clinical task. In
hemodialysis patients, troponins and natriuretic peptides have
consistently been shown to be closely associated with patient
mortality and improve risk prediction provided by clinical
variables alone [5–7]. In this context, the search for new
biomarkers reflecting different facts of cardiovascular risk is still
ongoing. Among these new biomarkers, the stable fragments MR-
pro-ADM, CT-pro-ET1 and copeptin are promising candidates to
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Table 1. Patient characteristics of the cohort (N = 239).
median age 70 (61; 77) years (n = 239)
gender distribution 64% male (n = 153)/36% female (n = 86)
renal disease
diabetic nephropathy 26% (n = 63)
hypertension 8% (n = 19)
glomerulonephritis 30% (n = 71)
polycystic disease 5% (n = 11)
other/unknown 31% (n = 75)
cardiac comorbidities
coronary heart disease/revascularized 31% (n = 74)/19% (n = 31)
valvular heart disease 26% (n = 61
atrial fibrillation 23% (n = 55)
pulmonary hypertension 7% (n = 16)
AICD carrier 2% (n = 4)
other comorbidities
LV dysfunction 25% (n = 59)
diabetes mellitus 38% (n = 90)
peripheral vascular disease 33% (n = 80)
stroke 16% (n = 38)
vasculitis 3% (n = 8)
malignoma 14% (n = 34)
COPD 8% (n = 19)
length of time on dialysis 46 (19; 85) months (n = 239)
duration of dialysis session 4.0 (4.0; 4.5) hours (n = 239)
dialysis access
arteriovenous fistula 71% (n = 169)
PTFE graft 13% (n = 31)
tunneled catheter 16% (n = 38)
dialysis membrane
high-flux 92% (n = 219)
low-flux 8% (n = 20)
residual diuresis 250 (0; 1000) mL/day (n = 239)
anuric patients 39% (n = 93)
interdialytic weight gain 1.85 (1.29; 2.47) kg (n = 239)
blood pump speed 300 (280; 340) mL/min (n = 239)
shunt flow 1080 (733; 1475) mL/min (n = 187)
blood pressure 134 (122; 144)/69 (63; 74) mm Hg (n = 239)
singe pool Kt/V 1.55 (1.40; 1.73) (n = 239)
laboratory data
hemoglobin 11.5 (11.1; 12.0) g/dL (n = 239)
C-reactive protein 8.6 (4.6; 15.0) mg/L (n = 239)
albumin 37.1 (35.4; 39.3) g/L (n = 239)
parathormone 204 (130; 348) pg/mL (n = 239)
b2-microglobulin 23.4 (19.4; 25.4) mg/L (n = 239)
high sensitive troponin T 49 (31; 73) pg/mL (n = 239)
NT-pro-BNP 4435 (1687; 16228) pg/mL (n = 223)
Values shown are the median and interquartile range. N indicates number of patients from whom data were available.
Abbreviations:
AICD automatic implantable cardioverter-defibrillator, COPD chronic obstructive pulmonary disease, PTFE polytetrafluorethylene, LV left ventricle.
doi:10.1371/journal.pone.0086148.t001
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further improve clinical risk assessment. Interestingly, pilot studies
by our group and others [8–12] have shown that in some settings,
these novel tools even outperform natriuretic peptides [8;9;12].
However, little is known in hemodialysis patients about the
performance and significance of measuring the plasma concen-
tration of MR-pro-ADM, CT-pro-ET1 and copeptin. Two recent
studies have shown that increased MR-pro-ADM and copeptin
levels were associated with reduced survival [13;14], however, data
about the prognostic value of CT-pro-ET1 are not available.
In our study, we analyzed the factors influencing the plasma
concentration of copeptin, MR-pro-ADM and CT-pro-ET1 in
stable ambulatory hemodialysis patients and analyzed the prog-
nostic value of each vasoactive peptide during a 3.8-year follow-
up.
Methods
Patients and cohort
This prospective multicenter study included stable ambulatory
hemodialysis patients from four dialysis centers in Southwest
Germany between September 2009 and April 2010. Patients were
included after they provided written informed consent and when
there was no evidence of an acute illness, a cardiac event or a
procedure within the previous two months. Patients with cardiac
diseases leading to increased cardiac biomarkers concentration
(troponin, natriuretic peptides) independent of ESRD, such as
amyloidosis were excluded. The study was approved by the local
ethics committee of the University of Tuebingen (191/2009BO2).
Laboratory assays
Plasma concentration of copeptin, MR-pro-ADM and CT-pro-
ET1 were measured in three independent samples taken within
2 weeks, each one taken to the start of a dialysis session. Blood was
collected in lithium-heparinized tubes (Sarstedt, Nuembrecht,
Germany), cooled at 4uC and centrifuged within 4 hours; the sera
were stored at 280uC for further analysis. The plasma concen-
trations of copeptin, MR-pro-ADM and CT-pro-ET1 were
measured using an automated immunoluminometric assay on a
Kryptor system (B.R.A.H.M.S AG, Henningsdorf, Germany) as
described in [2–4]. In healthy persons, the normal range defined
as the span between the 2.5th and 97.5th percentile was 1.7–11.3
pmol/L for copeptin [3], 0.17–0.49 nmol/L for MR-pro-ADM
[2] and 24.8–66.6 pmol/L for CT-pro-ET1 [4].
The plasma concentrations of high sensitive troponin T were
measured using an automated Roche assay on an Elecsys 2010
system (Roche, Basel, Switzerland). Plasma concentrations of NT-
pro-BNP were measured on a Siemens Immulite 2000 XPi system
according to the manufacturers instructions (Siemens Healthcare
Diagnostics, Eschborn, Germany). Plasma beta-2-microglobulin
concentrations were measured using a turbidimetric assay
(Randox Laboratories, Antrim, United Kingdom). All other
laboratory values (i.e., parathormone, hemoglobin, albumin and
C-reactive protein) were extracted from the patients’ medical
records and averaged from the available values of the previous
year (4–12 values).
Clinical data
From each patient data on residual diuresis (measured by 24 h
urine collection), single pool Kt/V (mean of last 4 values),
interdialytic weight gain, predialytic systolic and diastolic blood
pressure (means from the last 12 values beginning from the first
blood draw, resp.), dialysis access and membrane, time on dialysis,
blood pump flow and finally shunt flow (measured with a
Transonic system, Ithaca, NY, USA) were extracted. The systolic
left ventricular (LV) function was classified from available
echocardiography examinations.
Statistical analysis
Three plasma samples were available from 87% of the patients
and were averaged to calculate the arithmetic mean without
excluding possible outliers. Plasma vasoactive peptide concentra-
tions and continuous clinical data were log10 transformed to
approximate normal distribution. The association of the plasma
Figure 1. Box-and-Whisker-Plot of the plasma vasoactive peptide concentration indicating median, IQR and the range between the
2.5th and 97.5th percentile (Panel A). Solid lines represent the upper reference limit. Panel B: Box-and-Whisker-Plot of the plasma vasoactive
peptide concentration expressed as multiples of the upper reference limit.
doi:10.1371/journal.pone.0086148.g001
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vasoactive peptide concentration with clinical or dialysis-related
factors was analyzed by univariate parametric correlation. To
identify independent determinants of the plasma vasoactive
peptide concentration, multivariate linear regression analyses were
performed. Selection of the variables entering the model was
derived from forward-stepwise multiple linear regression, and all
variables with a p-value,0.20 were subsequently included in the
multivariate linear regression models. Finally, the residuals of each
model were tested for normality. The follow-up period started on
the first day of blood draw and lasted until October 26th, 2013.
Causes of death were classified according to the best knowledge of
each particular case. Cardiovascular death was considered as
sudden death (most probably circulatory or cardiac arrest) and
death due to a cardiovascular event or disease (coronary artery
disease, hypertensive crisis, stroke, peripheral artery disease). The
averaged values of the deceased patients were compared to those
from the surviving patients using a t-Test or Wilcoxons test.
Kaplan-Meier curves were generated after stratification into
tertiles of the variable according to its distribution. Survival curves
were compared using the log-rank test. Univariate and multivar-
iate proportional hazards were calculated using the Cox regression
analysis. Data analysis was performed using the statistical software
package JMP 10.0.1 (SAS Institute, Cary, NC).
Results
Patients
From a total of n = 250 available patients treated in the
participating centers, 239 patients (95.6%) were included in the
study. 6 patients declined written informed consent, 2 died within
the period of blood sampling, 2 had cardiac amyloidosis and one
patient was only recently initiated to dialysis. The characteristics of
the study cohort are given in table 1.
Plasma concentrations of copeptin, MR-pro-ADM and CT-
pro-ET1 in the cohort
In nearly all participating patients, the plasma concentrations of
all studied vasoactive peptide fragments were elevated compared
to the reference values from healthy persons. The median
concentration was 132 pmol/L (IQR 78–192) for copeptin, 1.26
pmol/L (IQR 1.02–1.80) for MR-pro-ADM and 149 pmol/L
(IQR 121–181) for CT-pro-ET1 (Figure 1A). Expressed as
multiples of the 97.5th percentile taken as the upper end of the
reference range obtained from healthy individuals [2–4], the
copeptin concentration was elevated 11.7-fold (IQR 6.9–16.9)
compared to 2.8-fold for MR-pro-ADM (IQR2.1–3.7) and 2.2-
fold for CT-pro-ET1 (IQR 1.8–2.7; Figure 1B).
Table 2. Univariate correlations (Pearsons r) of the plasma vasoactive peptide concentration with general and dialysis-specific
parameters (n = 210–239).
MR-pro-ADM, pmol/L CT-pro-ET1, pmol/L copeptin, pmol/L
dialysis-specific factors
age, y n.s. 20.24 *** n.s.
time on dialysis, months 0.34 *** 0.33 *** 0.30 ***
residual diuresis, ml/day 20.25 *** 20.23 *** 20.33 ***
interdialytic weight gain, kg 0.13 * 0.12 # 0.16 *
shunt flow, ml/min n.s. 0.26 *** 0.13 #
systolic blood pressure, mm Hg 20.18 ** n.s. n.s.
diastolic blood pressure, mm Hg n.s. 0.27 *** n.s.
pulse pressure, mmHg 20.17 ** 20.25 *** n.s.
duration of a HD session n.s. 0.17 * n.s.
blood pump speed, ml/min n.s. n.s. n.s.
laboratory data
Kt/V 0.11 # 0.25 *** 0.11 #
hemoglobin, g/dL n.s. n.s. n.s.
plasma albumin, g/L n.s. n.s. n.s.
C-reactive protein, mg/L 0.13 # 20.11 # n.s.
parathormone, pg/mL n.s. n.s. n.s.
b2-microglobulin, mg/dL 0.54 *** 0.57 ** 0.33 ***
troponin T, pg/mL 0.26 *** n.s. 0.26 ***
NT-pro-BNP, pg/mL 0.42 *** 0.24 ** 0.24 ***
comorbidity (1 = yes)
systolic LV dysfunction 0.17 * n.s. 0.13 #
valvular disease 0.28 *** 0.17 ** 0.18 **
atrial fibrillation 0.35 *** n.s. n.s.
pulmonary hypertension 0.17 ** n.s. n.s.
peripheral vascular disease 0.21 ** n.s. n.s.
diabetes mellitus n.s. 20.20 *** n.s.
# p,0.10, * p,0.05, ** p,0.01, *** p,0.001, n.s. = not significant (p.0.10).
doi:10.1371/journal.pone.0086148.t002
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Plasma vasoactive peptide concentrations were moderately
correlated to one another, with the highest correlation between
MR-pro-ADM and CT-pro-ET1 (0.45, p,0.0001), followed by
copeptin and CT-pro-ET1 (0.39, p,0.0001) and MR-pro-ADM
and copeptin (0.28, p,0.0001). Within three consecutive samples,
the intraindividual variability expressed as the coefficient of
variation was the least for CT-pro-ET1 (8612%), followed by
MR-pro-ADM (14611%) and copeptin (17614%).
Univariate analyses
Table 2 lists the results of the univariate correlation analyses of
the plasma vasoactive peptide concentration with the collected
parameters. MR-pro-ADM, copeptin and CT-pro-ET1 showed a
significant positive correlation to time on dialysis and the b2-
microglobulin concentration while they were all negatively
correlated to residual diuresis. MR-pro-ADM was negatively
correlated to systolic blood pressure, while CT-ET1 was positively
correlated to diastolic blood pressure. There was weak correlation
of all vasoactive peptides to Kt/V and interdialytic weight gain
and almost no correlation to cardiac comorbidity except for MR-
pro-ADM (table 2).
Multivariate analyses
To analyze the independent determinants of the plasma
vasoactive peptide concentration, a multivariate linear regression
model was performed with a stepwise forward approach based on
a p-value of,0.20 and all covariates from table 2. Table 3 lists the
resulting multivariate models. Plasma b2-microglobulin concen-
tration was the strongest independent determinant of the plasma
vasoactive peptide concentration. The modeling was best for
Table 3. Independent factors determining the plasma vasoactive peptide concentration by multivariate linear modeling (n = 155–
201).
covariate estimate ± SD
standardized
estimate ± SD p-value
MR-pro-ADM
R2=0.48
y-intercept 20.8560.41 0.1360.01
b2-microglobulin, mg/L 0.9760.10 0.2860.03 ,0.0001
duration of a HD session 0.6460.23 0.1360.05 0.0069
atrial fibrillation (1 = yes) 0.1360.02 0.0760.01 ,0.0001
systolic blood pressure, mmHg 20.4260.17 20.0760.03 0.0149
NT-proBNP, pg/ml 0.0360.02 0.0560.03 0.0933
interdialytic weight gain, kg 20.0360.02 20.0460.02 0.1196
peripheral vascular disease (1 = yes) 0.0660.02 0.0360.01 0.0061
valvular disease (1 = yes) 0.0360.02 0.0160.01 0.2180
CT-pro-ET1
R2=0.41
y-intercept 1.4360.40 2.1760.01
b2-microglobulin, mg/L 0.5660.07 0.1660.02 ,0.0001
NT-proBNP, pg/ml 0.0560.01 0.0760.02 0.0009
age, y 20.2560.08 20.0760.02 0.0013
diastolic blood pressure, mmHg 0.4360.15 0.0860.02 0.0035
systolic blood pressure, mmHg 20.3560.14 20.0660.02 0.0142
plasma albumin, g/L 0.1660.12 0.0660.05 0.1917
atrial fibrillation (1 = yes) 20.0160.02 20.0160.01 0.4668
copeptin
R2=0.19
y-intercept 0.7460.27 2.0860.02
b2-microglobulin, mg/L 0.6860.20 0.1860.05 0.0009
time on dialysis, months 0.1560.05 0.1460.04 0.0014
systolic LV dysfunction (1 = yes) 0.0960.04 0.0460.02 0.0292
parathormone, pg/mL 0.0760.05 0.0960.06 0.1156
Note that all continuous parameter were entered into the model after log10 transformation.
doi:10.1371/journal.pone.0086148.t003
Table 4. Follow-up data after 3.8 (IQR 3.6;3,9) years and
causes of death.
continued on HD 138 (57.7%)
transplanted 15 (6.3%)
deceased 86 (36.0%)
sudden death 20 (23% of all deaths)
cardiovascular death1 14 (16%)
infection and sepsis 12 (14%)
wasting/cachexia 20 (23%)
malignancy 9 (10%)
others/unknown 11 (13%)
1Composite of deaths due to coronary artery disease, hypertension, peripheral
artery disease.
doi:10.1371/journal.pone.0086148.t004
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MR-pro-ADM and CT-pro-ET1 with an adjusted r2 value of 0.48
and 0.41, respectively, and poor for copeptin (r2 = 0.18).
Prognostic value
After 3.8 years of follow-up, data from all 239 patients were
available (median follow-up time 1378 days [IQR 1325; 1429]).
Of those, 86 had died (36%), 15 (6%) had been transplanted and
the rest remained on HD (table 4). The concentration of MR-pro-
ADM was significantly (p,0.0001) higher in the deceased patients
compared to the surviving patients (1.62 pmol/L [IQR 1.19;2.27]
vs. 1.26 pmol/L [IQR 0.98;1.66]). The concentrations of CT-pro-
ET1 and copeptin were not different in the surviving patients
compared to the deceased patients (p = 0.52 and p=0.07,
respectively).
The survival curves stratified for tertiles of vasoactive peptide
concentrations are shown in Figure 2, and the relative risk
compared to the first tertile is shown in Figure 3. Using the Cox
proportional hazard method, plasma MR-pro-ADM concentra-
tion was found to be significantly associated with increased all-
cause and cardiovascular mortality in a univariate analysis (hazard
ratio for a 10-fold increase 9.94 and 34.87, respectively; table 5).
These associations were stable in a model adjusted for dialysis-
specific factors and finally attenuated in a model adjusted for all
prognostic factors. Plasma copeptin concentration was weakly
associated with all-cause (p = 0.077) and cardiovascular mortality
(p = 0.033) in a univariate model, and lost its associations in
multivariate analyses. Plasma CT-pro-ET1 concentration was not
associated with a significantly increased hazard ratio, both in
univariate and multivariate analyses.
Discussion
This study demonstrates that the plasma MR-pro-ADM
concentration is a strong predictor of mortality in hemodialysis
patients, whereas copeptin was only weakly and CT-pro-ET1
concentrations not at all associated with mortality. Similar results
have been published for MR-pro-ADM in hemodialysis patients
by Gouya et al. in 2011 [13], who reported a two-threefold
increased hazard ratio for mortality of the upper tertile of the
patients compared to the lower tertile. The association of the
plasma copeptin concentration with mortality has been previously
reported in a study with the cohort of the 4D study (German
Diabetes Dialysis Study) [14]. In that large study, copeptin was
significantly associated with both all-cause and cardiovascular
death, however, we could only demonstrate that copeptin was
weakly associated with cardiovascular mortality. The reason for
this discrepancy could be related to the studied cohort and
statistical power since the 4D study comprised 1241 solely diabetic
patients reaching the end point by 37–49%. To our knowledge,
the results presented on CT-pro-ET1 in this study are reported for
the first time and show that the plasma CT-pro-ET1 concentra-
tion is not predictive of mortality in hemodialysis patients. Data on
Figure 2. Survival curves of the cohort stratified according to the tertiles (T1, T2 and T3) of MR-pro-ADM (,1.09; 1.09–1.64; .1.64
pmol/L), CT-pro-ET1 (,131; 131–171; .171 pmol/L) and copeptin (,101; 101–171; .171 pmol/L) plasma concentration.
doi:10.1371/journal.pone.0086148.g002
Figure 3. Relative hazard ratios for all-cause mortality and cardiovascular mortality with 95% confidence interval according to the
tertiles (T1. T2 and T3) of MR-pro-ADM (,1.09; 1.09–1.64; .1.64 pmol/L), CT-pro-ET1 (,131; 131–171; .171 pmol/L) and copeptin
(,101; 101–171; .171 pmol/L) plasma concentration. The risk of the first tertile was set to 1. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0086148.g003
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big endothelin 1, the 38 amino acid precursor molecule of
endothelin 1, have shown a modest association with mortality in
hemodialysis patients, which was lost during multivariate modeling
[15]. The CT-pro-ET1 assay used in this study measures a
fragment at the C-terminus comprising amino acid residues 168
through 212 of the initial large precursor molecule pre-pro-ET1
(212 amino acids) [4] from which big endothelin 1 (amino acids
residues 53–90) and finally endothelin 1 (amino acid residues 53–
73) are derived. The reason why the fragment CT-pro-ET1,
although elevated in nearly all studied patients, failed to be
associated with mortality in contrast to patients with heart failure
[16] or patients after acute myocardial infarction [17] remains
unclear.
Both endothelin and vasopressin cause vasoconstriction, while
adrenomedullin is a peptide with strong vasodilating effects. The
association of MR-pro-ADM with mortality suggests that an
increased vasodilatory response in hemodialysis patients is
prognostically relevant and that low levels of MR-pro-ADM
represent a state of less vasoconstriction and better prognosis. The
finding of increased cardiovascular mortality with increased
copeptin concentrations supports this notion. In addition, it is
also conceivable that there is a resistance to the vasodilatory
response of MR-pro-ADM in hemodialysis patients leading to
increased secretion. In a study with stable kidney transplant
recipients, MR-pro-ADM concentrations correlated with the
resistance to antihypertensive treatment which suggests increased
vasoconstriction in these patients [18]. Studies from Yoshihara
et al. found that MR-pro-ADM plasma concentrations reflected
volume overload [19;20]. In this context, increased MR-pro-ADM
plasma concentration can be interpreted as a counterregulatory
response similar to the increase in the plasma concentration of the
natriuretic peptides which are strong predictors of mortality [11]
and also exert vasodilating effects [21]. Physiologically, adreno-
medullin mRNA is found in the adrenal gland, heart, kidney and
blood vessels and up-regulated by inflammation, hypoxia,
oxidative and mechanical shear stress, activation of the renin-
angiotensin and the sympathetic nervous system [22]. Pharmaco-
logical application of adrenomedullin has shown protective effects
in models of renal [23] or heart failure [24]. From this perspective,
adrenomedullin can be considered as a marker of stress in
cardiovascular disease, and particularly in patients with renal
failure who have all the above mentioned features.
Our data show that the plasma concentrations of MR-pro-
ADM, CT-pro-ET1 and copeptin were greatly increased in
hemodialysis patients, most likely reflecting accumulation. This
result was particularly true for copeptin, which was increased
about tenfold above the upper limit. This finding indicates that the
clearance of these peptide fragments is highly impaired during
dialysis-dependent chronic kidney disease, which is typical for low
molecular weight proteins. A marker of the latter is b2-
microglobulin (molecular weight 11.7 kDa), which was a strong
independent predictor of the plasma concentration of all
vasoactive peptides studied. On the other hand, modern dialysis
practices such as high flux dialyzers or hemodiafiltration can
remove significant amounts of low-molecular weight proteins as
this was known for b2-microglobulin [25] and also was shown for
Table 5. Hazard ratios (and 95% CIs) for mortality according to the MR-pro-ADM, CT-pro-ET1 and copeptin levels.
univariate (crude) multivariate: model 1 multivariate: model 2
HR with 95% CI p-value HR with 95% CI p-value HR with 95% CI p-value
MR-pro-ADM
all-cause mortality 9.94 [3.14–31.89] ,0.0001 9.54 [1.81–51.17] 0.0079 3.37 [0.82–14.88] 0.0924
cardio-vascular mortality 34.87 [5.58;217] 0.0001 101.26 [5.47;2317] 0.0017 6.14 [0.66; 71.92] 0.1138
CT-pro-ET1
all-cause mortality 1.21 [0.25–6.18] 0.8185 3.52 [0.29–43.31] 0.3212 3.10 [0.47–21.97] 0.2427
cardio-vascular mortality 2.27 [0.18;32.63] 0.5293 2.75 [0.28;27.29] 0.3813 5.57 [0.26;138.83] 0.2741
copeptin
all-cause mortality 2.01 [0.92–4.66] 0.0770 2.37 [0.56–11.58] 0.2492 0.97 [0.39–2.60] 0.9550
cardio-vascular mortality 4.24 [1.11;19.57] 0.0334 5.95 [0.81;63.43] 0.0824 2.62 [0.50;17.61] 0.2669
The hazard ratios are displayed for a one-unit increase in the decadic log-transformed (corresponding to a ten-fold increase) of the plasma MR-pro-ADM, CT-pro-ET1 and
copeptin concentration. Cardiovascular mortality was considered as sudden death (most probably circulatory or cardiac arrest) and death due to a cardiovascular event
or disease (coronary artery disease, hypertensive crisis, stroke, peripheral artery disease).
Model 1: adjusted for demographics, hemodynamic and dialysis-specific risk factors.
- age.
- gender (male).
- time on dialysis.
- residual diuresis.
- shunt flow.
- vascular access on study enrolment (fistula, graft or catheter).
- systolic and diastolic blood pressure.
- interdialytic weight gain.
- pooled Kt/V.
Model 2: adjusted for all factors associated with mortality (significant difference between deceased and surviving patients).
- age.
- body mass index.
- duration of HD session.
- diastolic blood pressure.
- secondary hyperparathyroidism (represented by parathormone concentration).
- inflammatory status (represented by CRP concentration).
- comorbidities: systolic dysfunction (1 = yes), peripheral vascular disease (1 = yes), coronary artery disease (1 = yes), atrial fibrillation (1 = yes).
doi:10.1371/journal.pone.0086148.t005
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MR-pro-ADM [19]. In that study the plasma MR-pro-ADM
concentration was approximately 25–30% lower after a hemodi-
alysis session. Hence, hemodialysis patients reach a new steady
state at a higher level.
The increased plasma concentrations complicate the interpre-
tation of MR-pro-ADM, copeptin and CT-pro-ET1 values, but
one has to consider that accumulation can only occur when these
peptides are released from their original sites upon biological
stimuli, therefore we must assume that there is an increased release
of these peptides in hemodialysis patients. The increased plasma
concentrations in turn, however, make the interpretation more
difficult and only with the aid of studies such as this, clinically
meaningful cut-off values can be derived such as the limit of the
upper tertile for the prognostic use of MR-pro-ADM (i.e. .1.62
pmol/L). However, more studies are needed to better define cut-
off values of the plasma concentration of these peptides for
diagnostic and prognostic purposes.
The limitations of the current study might include the
incomplete collection of the data relevant to understand the
correlation of the studied parameters. In the multivariate
regression model, .50% of the variance was not explained by
the entered factors, in the case of copeptin even .80%. The study
focused on nephrological parameters that are commonly available
and accessible during hemodialysis treatment, such as residual
diuresis or shunt flow. Furthermore, survival analyses might be
limited by the low mortality during the follow-up period.
In conclusion, the fragments of the vasoactive peptides MR-pro-
ADM, CT-pro-ET1 and copeptin are largely elevated in
hemodialysis patients because of accumulation and, most likely,
higher release. Plasma MR-pro-ADM concentration was strongly
associated with all-cause and cardiovascular mortality.
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